Get the Stockscreener App
1.58
1.25%
-0.02
Pre-market:
1.56
-0.02
-1.27%
Heron Therapeutics Inc stock is traded at $1.58, with a volume of 701.81K.
It is down -1.25% in the last 24 hours and up +47.66% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.60
Open:
$1.6
24h Volume:
701.81K
Relative Volume:
0.24
Market Cap:
$240.31M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-1.3504
EPS:
-1.17
Net Cash Flow:
$-9.61M
1W Performance:
-4.24%
1M Performance:
+47.66%
6M Performance:
-50.31%
1Y Performance:
-11.73%
1-Day Range:
$1.56
$1.61
1-Week Range:
$1.46
$1.67
52-Week Range:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.58 | 240.31M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Heron Therapeutics Relocates Headquarters to North Carolina - TipRanks
Heron Therapeutics Relocates HQ to Research Triangle Park, Marking Strategic Biotech Hub Move - StockTitan
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to “Hold” at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Cut to "Hold" at StockNews.com - MarketBeat
Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lowered by Charles Schwab Investment Management Inc. - Defense World
U.S. District Court Upholds Validity of CINVANTI® Patents - The Eastern Progress Online
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - The Eastern Progress Online
StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to "Buy" - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com - Defense World
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - Kilgore News Herald
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - The Eastern Progress Online
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - Defense World
Relief For Heron Therapeutics After The Court Win On Cinvanti - Seeking Alpha
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Heron Therapeutics wins patent case for CINVANTI drug - Investing.com
Heron Therapeutics wins patent case for CINVANTI drug By Investing.com - Investing.com Canada
Heron Therapeutics Shares Soar 91% on Patent Dispute Win - MarketWatch
Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan
Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues (NASDAQ:HRTX) - Seeking Alpha
Biotech Finds Mid-Week Success Following Q4 Earnings Release - MSN
Principal Financial Group Inc. Has $204,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to “Hold” - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold" - MarketBeat
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Q3 2024 Earnings Preview - MSN
Heron Therapeutics Inc (NASDAQ: HRTX) Declines -1.68%: This $177.95 million Stock Could Go Down -669.23% - Stocks Register
Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0% - MarketBeat
Northland Capmk Has Pessimistic View of HRTX Q4 Earnings - Defense World
Equities Analysts Set Expectations for HRTX Q4 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Raised to Buy at StockNews.com - Defense World
Heron Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Has Lowered Expectations for Heron Therapeutics (NASDAQ:HRTX) Stock Price - MarketBeat
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge - Simply Wall St
Heron Therapeutics Inc (HRTX) Quarterly 10-Q Report - Quartz
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30% - Simply Wall St
Earnings call: Heron Therapeutics projects higher Q4 revenue By Investing.com - Investing.com UK
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance - TipRanks
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Heron Therapeutics reports Q3 EPS (3c), consensus (3c) - TipRanks
Heron Therapeutics (HRTX) Set to Announce Earnings on Tuesday - Defense World
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):